Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data
Objectives To compare the time to treatment failure, remission and first seizure of 12 AEDs
(carbamazepine, phenytoin, sodium valproate, phenobarbitone, oxcarbazepine, lamotrigine …
(carbamazepine, phenytoin, sodium valproate, phenobarbitone, oxcarbazepine, lamotrigine …
Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis
Abstract Background Brivaracetam (BRV), cenobamate (CNB), eslicarbazepine acetate
(ESL), lacosamide (LCM) and perampanel (PER) are antiseizure medications (ASMs) …
(ESL), lacosamide (LCM) and perampanel (PER) are antiseizure medications (ASMs) …
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
O Devinsky, R Nabbout, I Miller, L Laux… - …, 2019 - Wiley Online Library
Objective Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet
syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B …
syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B …
Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial
Objective Add‐on cannabidiol (CBD) reduced seizures associated with Dravet syndrome
(DS) in two randomized, double‐blind, placebo‐controlled trials: GWPCARE1 Part B …
(DS) in two randomized, double‐blind, placebo‐controlled trials: GWPCARE1 Part B …
Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures
Background and Objectives To evaluate long-term efficacy (percent seizure frequency
reduction and responder rates), safety, and tolerability of adjunctive cenobamate (CNB) in …
reduction and responder rates), safety, and tolerability of adjunctive cenobamate (CNB) in …
Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open‐label extension of a randomized clinical study
Objective This study was undertaken to examine long‐term (up to 7.8 years) retention rate,
safety, and tolerability of the antiseizure medication (ASM) cenobamate as adjunctive …
safety, and tolerability of the antiseizure medication (ASM) cenobamate as adjunctive …
A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study
Objective There are few comparative data on the third‐generation antiseizure medications
(ASMs). We aimed to assess and compare the effectiveness of brivaracetam (BRV) …
(ASMs). We aimed to assess and compare the effectiveness of brivaracetam (BRV) …
The adverse-effect profile of lacosamide
J Li, M Sun, X Wang - Expert Opinion on Drug Safety, 2020 - Taylor & Francis
Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe
and Asia since it was approved by the FDA in 2008. Many patients have benefited from this …
and Asia since it was approved by the FDA in 2008. Many patients have benefited from this …
Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study
Y Winter, R Abou Dargham, S Patiño Tobón, S Groppa… - CNS drugs, 2024 - Springer
Abstract Background and Objectives Cenobamate (CNB) is a new antiseizure medication
(ASM) to treat drug-resistant, focal-onset seizures. Data on its use in early therapy lines are …
(ASM) to treat drug-resistant, focal-onset seizures. Data on its use in early therapy lines are …
Involvement of peroxisome proliferator-activated receptor γ in anticonvulsant activity of α-asaronol against pentylenetetrazole-induced seizures in zebrafish
In mammals, peroxisome proliferators activated receptors (PPARs), the nuclear hormone
receptors, have been reported to be involved in seizure control. Selective agonists and …
receptors, have been reported to be involved in seizure control. Selective agonists and …